Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Trial details
- Registry ID
- NCT05130866
- Drugs studied
- REC-2282
TrialRedline tracks 6 clinical trials sponsored by Recursion Pharmaceuticals Inc.: 1 Phase 2 / 3, 3 Phase 2, 2 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasNCT05130866 | REC-2282 | Terminated | 2025-08-18Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| The Symptomatic Cerebral Cavernous Malformation Trial of REC-994NCT05085561 | REC-994 | Completed | 2025-06-30Actual |
| The Clostridioides Difficile Trial of REC-3964NCT06536465 | REC-3964 | Terminated | 2025-05-06Actual |
| A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC MutationNCT06005974 | REC-4881 | Terminated | 2025-02-24Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| REC-7735 in Participants With Solid TumorsNCT07819136 | REC-7735 | Recruiting | 2031-01Estimated |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerNCT06678659 | REC-1245 | Recruiting | 2029-07Estimated |
Names as written in the registry records.
NCT05085561 · Recursion Pharmaceuticals Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence and severity of adverse events (AEs) Time frame: Up to 24 months. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: A TEAE was the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. TEAES which include treatment related TEAEs, serious TEAEs, treatment-related serious TEAEs, TEAEs leading to treatment discontinuation, and treatment-related TEAEs leading to treatment discontinuation are reported. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section Time frame: Up to a maximum of 1201 days.
NCT06005974 · Recursion Pharmaceuticals Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate the safety and tolerability of REC-4881 Measure: To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR). After: Measure: Number of Participants with Dose Limiting Toxicities Measure: Objective Response Rate.
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 18 participants (actual).
Before: Estimated. After: Actual.
Before: Jan 2027. After: 24 Feb 2025.
Before: Active not recruiting. After: Terminated.